CN101155914B - 树状细胞组合物和方法 - Google Patents

树状细胞组合物和方法 Download PDF

Info

Publication number
CN101155914B
CN101155914B CN2006800113802A CN200680011380A CN101155914B CN 101155914 B CN101155914 B CN 101155914B CN 2006800113802 A CN2006800113802 A CN 2006800113802A CN 200680011380 A CN200680011380 A CN 200680011380A CN 101155914 B CN101155914 B CN 101155914B
Authority
CN
China
Prior art keywords
cells
dendritic cells
monocytes
rna
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800113802A
Other languages
English (en)
Chinese (zh)
Other versions
CN101155914A (zh
Inventor
R·波格-卡利
T·莫内史密斯
I·切尔帕诺瓦
L·丁特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merix Bioscience Inc
Original Assignee
Kirin Pharma KK
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Pharma KK, Merix Bioscience Inc filed Critical Kirin Pharma KK
Publication of CN101155914A publication Critical patent/CN101155914A/zh
Application granted granted Critical
Publication of CN101155914B publication Critical patent/CN101155914B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2006800113802A 2005-04-08 2006-04-07 树状细胞组合物和方法 Expired - Fee Related CN101155914B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66946805P 2005-04-08 2005-04-08
US60/669,468 2005-04-08
PCT/US2006/013159 WO2006127150A2 (en) 2005-04-08 2006-04-07 Dendritic cell compositions and methods

Publications (2)

Publication Number Publication Date
CN101155914A CN101155914A (zh) 2008-04-02
CN101155914B true CN101155914B (zh) 2013-03-06

Family

ID=36992670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800113802A Expired - Fee Related CN101155914B (zh) 2005-04-08 2006-04-07 树状细胞组合物和方法

Country Status (12)

Country Link
US (6) USRE46152E1 (cg-RX-API-DMAC7.html)
EP (1) EP1882031B1 (cg-RX-API-DMAC7.html)
JP (1) JP5020935B2 (cg-RX-API-DMAC7.html)
KR (6) KR20170086700A (cg-RX-API-DMAC7.html)
CN (1) CN101155914B (cg-RX-API-DMAC7.html)
AU (1) AU2006249640C1 (cg-RX-API-DMAC7.html)
CA (1) CA2602434C (cg-RX-API-DMAC7.html)
ES (1) ES2650569T3 (cg-RX-API-DMAC7.html)
IL (2) IL185977A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007012221A (cg-RX-API-DMAC7.html)
NO (1) NO345353B1 (cg-RX-API-DMAC7.html)
WO (1) WO2006127150A2 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2007065439A1 (en) * 2005-12-08 2007-06-14 Dandrit Biotech A/S Method for generating dendritic cells employing decreased temperature
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
KR100935826B1 (ko) 2007-11-27 2010-01-08 주식회사 바이넥스 부유밀도구배 원심분리를 이용하여 말초혈액단핵구로부터 단세포를 분리하는 방법
US8513208B2 (en) 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
WO2009120891A2 (en) * 2008-03-27 2009-10-01 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
KR20110081336A (ko) * 2008-11-04 2011-07-13 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 2 발현의 조절
WO2011032161A2 (en) 2009-09-14 2011-03-17 Baylor Research Institute Vaccines directed to langerhans cells
BR112012014104A2 (pt) * 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
DK2552410T3 (en) 2010-03-31 2019-02-18 Stabilitech Biopharma Ltd PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
US20130011438A1 (en) * 2011-07-05 2013-01-10 SOTIO a.s. Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
EP2857498B1 (en) * 2012-05-31 2018-04-25 JW Creagene Inc. Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
AU2014213009B2 (en) * 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
TWI656839B (zh) * 2013-03-15 2019-04-21 健臻公司 高密度細胞儲存方法
ES2777304T3 (es) * 2014-02-21 2020-08-04 Colmmune Inc Células TSCM y métodos de uso
CN103948917A (zh) * 2014-04-02 2014-07-30 江苏和泽生物科技有限公司 树突状细胞疫苗的制备方法
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
KR101518972B1 (ko) 2014-08-01 2015-05-18 제이더블유크레아젠 주식회사 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도
EP3957173A1 (en) 2014-09-18 2022-02-23 Genzyme Corporation Ultra-high density cell banking methods
WO2016076428A1 (ja) 2014-11-14 2016-05-19 日本赤十字社 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
WO2016179001A1 (en) * 2015-05-01 2016-11-10 Baylor College Of Medicine Methods for enhancing an immune response with a ctla-4 antagonist
CN107921063A (zh) * 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
US11612652B2 (en) * 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP6779616B2 (ja) * 2015-12-25 2020-11-04 富士ソフト株式会社 Ｎｋｔ細胞活性化医薬組成物、その製造方法、及び抗原提示細胞の保存方法
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
JP2021502419A (ja) * 2017-11-07 2021-01-28 コイミューン インコーポレイテッド 樹状細胞治療のための方法および使用
TW201924722A (zh) 2017-12-05 2019-07-01 美商Ｐｄｓ生技公司 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
WO2019136155A1 (en) * 2018-01-08 2019-07-11 The Regents Of The University Of Michigan Aldh1 antigen-pulsed dendritic cells
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
CN114621921A (zh) * 2020-12-11 2022-06-14 深圳先进技术研究院 一种提取神经突触体的方法
CN117881794A (zh) * 2021-06-30 2024-04-12 诺瓦瑟拉姆株式会社 制备包含血中循环肿瘤细胞的试样的方法
CN113980901B (zh) * 2021-12-28 2022-06-17 上海惠盾因泰生物科技有限公司 一种制备高纯度的成熟人树突状细胞的方法及应用
EP4544028A4 (en) * 2022-06-24 2026-05-20 Lihpao Life Science Corp PROCESS FOR THE PRODUCTION OF MATURE DENDRITIC CELLS
US12642618B2 (en) * 2023-01-04 2026-06-02 Sheridan O'Neal Carriers for collecting biological samples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1360628A (zh) * 1999-05-28 2002-07-24 格内拉股份公司 一种将抗原转移到树突状细胞的方法
CN1517435A (zh) * 2003-01-17 2004-08-04 江西医学院 白血病细胞诱导生成树突状细胞的培养基及其培养方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
KR20000022445A (ko) 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
US20050084966A1 (en) 1999-04-20 2005-04-21 Edelson Richard L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells
WO2000062818A1 (en) 1999-04-20 2000-10-26 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US20050158856A1 (en) 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
EP1270732A1 (en) 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
FR2833271B1 (fr) 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
JP4567446B2 (ja) 2002-06-19 2010-10-20 ノースウエスト バイオセラピューティクス，インコーポレイティド 白血球富化のための平行流濾過デバイスおよび方法
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
US20060239962A1 (en) 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
ATE420946T1 (de) 2003-02-27 2009-01-15 Northwest Biotherapeutics Inc Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine
CA2577320C (en) 2004-09-14 2019-08-13 Argos Therapeutics, Inc. Strain-independent amplification of pathogens and vaccines thereto
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1360628A (zh) * 1999-05-28 2002-07-24 格内拉股份公司 一种将抗原转移到树突状细胞的方法
CN1517435A (zh) * 2003-01-17 2004-08-04 江西医学院 白血病细胞诱导生成树突状细胞的培养基及其培养方法与应用

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Jonuleit H, et al,.Pro-inflammatory cytokines and prostaglandins inducematuration of potent immunosimulatory dendritic cells underfetal calf serum-free conditions.European Journal of Immunology27 12.1997,27(12),3135-3142.
Jonuleit H, et al,.Pro-inflammatory cytokines and prostaglandins inducematuration of potent immunosimulatory dendritic cells underfetal calf serum-free conditions.European Journal of Immunology27 12.1997,27(12),3135-3142. *
Koya RC, et al,.Potent Maturation of Monocyte-derived Dendritic Cells AfterCD40L Lentiviral Gene Delivery.Journal of Immunotherapy26 5.2003,26(5),451-460.
Koya RC, et al,.Potent Maturation of Monocyte-derived Dendritic Cells AfterCD40L Lentiviral Gene Delivery.Journal of Immunotherapy26 5.2003,26(5),451-460. *
Liu Y, et al,.Adenovirus-mediated CD40 ligand gene-engineered dendriticcells elicit enhanced CD8+ cytotoxic T-cell activation andantitumor immunity.Cancer Gene Therapy9.2002,9202-208. *
Mohamadzadeh M, et al,.Interleukin 15skews monocyte differentiation intodendriticcells.Journal of Experimental Medicine194 7.2001,194(7),1013-1019.
Mohamadzadeh M, et al,.Interleukin 15skews monocyte differentiation intodendriticcells.Journal of Experimental Medicine194 7.2001,194(7),1013-1019. *
Sallusto F, et al,.Efficient Presentation of Soluble Antigen by CulturedHumanDendritic Cells Is Maintained byGranulocyte/MacrophageColony-stimulating Factor PlusIuterleukin 4 andDownregulated by Tumor Necrosis Factor a.Journal of Experimental Medicine179 4.1994,179(4),1109-1118.
Sallusto F, et al,.Efficient Presentation of Soluble Antigen by CulturedHumanDendritic Cells Is Maintained byGranulocyte/MacrophageColony-stimulating Factor PlusIuterleukin 4 andDownregulated by Tumor Necrosis Factor a.Journal of Experimental Medicine179 4.1994,179(4),1109-1118. *

Also Published As

Publication number Publication date
KR20130061753A (ko) 2013-06-11
WO2006127150A2 (en) 2006-11-30
AU2006249640A1 (en) 2006-11-30
KR20160045151A (ko) 2016-04-26
US20120114680A1 (en) 2012-05-10
IL231889A0 (en) 2014-05-28
US20160102291A1 (en) 2016-04-14
US20130280805A1 (en) 2013-10-24
JP2008535493A (ja) 2008-09-04
WO2006127150A3 (en) 2007-03-15
IL185977A0 (en) 2008-01-20
MX2007012221A (es) 2008-03-18
AU2006249640C1 (en) 2016-10-13
JP5020935B2 (ja) 2012-09-05
US8153425B2 (en) 2012-04-10
KR20150032915A (ko) 2015-03-30
CA2602434A1 (en) 2006-11-30
KR20170086700A (ko) 2017-07-26
US20150132844A1 (en) 2015-05-14
US20090053251A1 (en) 2009-02-26
NO20075166L (no) 2007-12-27
EP1882031B1 (en) 2017-11-08
ES2650569T3 (es) 2018-01-19
AU2006249640B2 (en) 2011-07-21
NO345353B1 (no) 2020-12-21
CN101155914A (zh) 2008-04-02
KR20200072566A (ko) 2020-06-22
KR20070119727A (ko) 2007-12-20
USRE46152E1 (en) 2016-09-20
IL231889A (en) 2016-10-31
KR101368035B1 (ko) 2014-02-26
US8501470B2 (en) 2013-08-06
CA2602434C (en) 2016-06-07
EP1882031A2 (en) 2008-01-30

Similar Documents

Publication Publication Date Title
KR101368035B1 (ko) 수지상 세포 조성물 및 방법
KR101243577B1 (ko) 성숙 수지상 세포 조성물 및 그의 배양 방법
JP5954918B2 (ja) 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
US20170096639A1 (en) Mature Dendritic Cell Compositions and Methods for Culturing Same
JP2018531022A (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
HK40051623A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
AU2013206016B2 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK1109422B (en) Dendritic cell compositions and methods
HK1109422A (en) Dendritic cell compositions and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: KYOWA HAKKO KIRIN CO., LTD.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20101009

Address after: North Carolina

Applicant after: Argos Therapeutics, Inc.

Address before: North Carolina

Applicant before: Argos Therapeutics, Inc.

Co-applicant before: Kyowa Hakko Kirin Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20080402

Assignee: Lummy (Hongkong) Co. Ltd.

Assignor: Argos Therapeutics, Inc.

Contract record no.: 2015990001055

Denomination of invention: Dendritic cell compositions and methods

Granted publication date: 20130306

License type: Exclusive License

Record date: 20151218

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130306